PL2563408T3 - Ultradrobne nanocząstki z funkcjonalizowaną matrycą poliorganosiloksanową i zawierające kompleksy metali; sposoby ich wytwarzania i ich zastosowania w obrazowaniu medycznym - Google Patents

Ultradrobne nanocząstki z funkcjonalizowaną matrycą poliorganosiloksanową i zawierające kompleksy metali; sposoby ich wytwarzania i ich zastosowania w obrazowaniu medycznym

Info

Publication number
PL2563408T3
PL2563408T3 PL11716589T PL11716589T PL2563408T3 PL 2563408 T3 PL2563408 T3 PL 2563408T3 PL 11716589 T PL11716589 T PL 11716589T PL 11716589 T PL11716589 T PL 11716589T PL 2563408 T3 PL2563408 T3 PL 2563408T3
Authority
PL
Poland
Prior art keywords
medical imaging
metal complexes
including metal
obtaining same
ultrafine nanoparticles
Prior art date
Application number
PL11716589T
Other languages
English (en)
Inventor
François LUX
Olivier Tillement
Maxime Saint Jean
Pierre Mowat
Pascal Perriat
Stéphane Roux
Anna Mignot
Original Assignee
Nano H
Université Lyon 1 Claude Bernard
Institut National Des Sciences Appliquées De Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nano H, Université Lyon 1 Claude Bernard, Institut National Des Sciences Appliquées De Lyon filed Critical Nano H
Publication of PL2563408T3 publication Critical patent/PL2563408T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL11716589T 2010-04-30 2011-05-02 Ultradrobne nanocząstki z funkcjonalizowaną matrycą poliorganosiloksanową i zawierające kompleksy metali; sposoby ich wytwarzania i ich zastosowania w obrazowaniu medycznym PL2563408T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1053389A FR2959502B1 (fr) 2010-04-30 2010-04-30 Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
EP11716589.4A EP2563408B1 (fr) 2010-04-30 2011-05-02 Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques; leur procede d'obtention et leurs applications en imagerie medicale
PCT/EP2011/056972 WO2011135101A2 (fr) 2010-04-30 2011-05-02 Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie

Publications (1)

Publication Number Publication Date
PL2563408T3 true PL2563408T3 (pl) 2019-09-30

Family

ID=43384584

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11716589T PL2563408T3 (pl) 2010-04-30 2011-05-02 Ultradrobne nanocząstki z funkcjonalizowaną matrycą poliorganosiloksanową i zawierające kompleksy metali; sposoby ich wytwarzania i ich zastosowania w obrazowaniu medycznym

Country Status (11)

Country Link
US (4) US20130195766A1 (pl)
EP (2) EP3517136A1 (pl)
DK (1) DK2563408T3 (pl)
ES (1) ES2731649T3 (pl)
FR (1) FR2959502B1 (pl)
HU (1) HUE044384T4 (pl)
PL (1) PL2563408T3 (pl)
PT (1) PT2563408T (pl)
SI (1) SI2563408T1 (pl)
TR (1) TR201909432T4 (pl)
WO (1) WO2011135101A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2959502B1 (fr) 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
FR2989280B1 (fr) * 2012-04-13 2017-02-24 Univ Claude Bernard Lyon Nanoparticules ultrafines comme agent de contraste multimodal
US10472556B2 (en) 2014-12-15 2019-11-12 Total Sa Nano-inhibitors
EP3192530A1 (fr) 2016-01-15 2017-07-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nanoparticules ultrafines comme agent d'imagerie pour el diagnostic d'une dysfonction rénale
CN110382010A (zh) 2016-12-08 2019-10-25 布里格姆妇女医院 铋-钆纳米颗粒
EP3634497A2 (en) 2017-06-09 2020-04-15 Nh Theraguix Method for synthesizing silica nanoparticles
JP2020523383A (ja) * 2017-06-14 2020-08-06 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）指向性ナノ粒子
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
FR3072281B1 (fr) * 2017-10-13 2020-12-04 Nh Theraguix Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs
FR3075649A1 (fr) * 2017-12-22 2019-06-28 Mexbrain Dispositif pour le maintien de l'homeostasie metallique, et ses utilisations
JP7431940B2 (ja) 2019-07-29 2024-02-15 エヌアッシュ テラギ 腫瘍を治療するための方法
FR3099883A1 (fr) 2019-08-14 2021-02-19 Nh Theraguix Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence
EP3795178A1 (en) 2019-09-19 2021-03-24 Nh Theraguix Methods for triggering m1 macrophage polarization
US12458709B2 (en) * 2019-12-11 2025-11-04 Novocure Gmbh Compositions and methods for imaging a cell
JP2023528240A (ja) 2020-05-15 2023-07-04 ウニヴェルシテ クロード ベルナール リヨン １ 画像誘導放射線療法のための方法
FR3116197A1 (fr) 2020-11-19 2022-05-20 Nh Theraguix Procédé de traitement de tumeurs par captation du cuivre et/ou du fer
FR3116216B1 (fr) 2020-11-19 2023-10-27 Nh Theraguix Procédé de préparation de nanoparticules
KR20250133269A (ko) 2022-07-13 2025-09-05 유니베르시테 드 몽펠리에 나노입자 및 방사성 의약품을 사용한 조합 요법
WO2024083937A2 (en) 2022-10-18 2024-04-25 Nh Theraguix Methods for imaging using spcct
WO2024236048A1 (en) 2023-05-16 2024-11-21 Nh Theraguix Combination therapy for treating tumors with radiotherapy
FR3151755A1 (fr) 2023-07-31 2025-02-07 Nh Theraguix Procédé de quantification de la concentration d’un agent de contraste et dispositif associé
WO2025072955A1 (en) * 2023-09-30 2025-04-03 The Brigham And Women's Hospital, Inc. Novel compositions, methods of manufacture and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024235A2 (en) * 2000-05-12 2002-03-28 University Hospital Prochelators of radiometal labeled molecules
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
FR2867180B1 (fr) * 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
US20090317335A1 (en) * 2006-04-20 2009-12-24 Wenbin Lin Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
FR2922106B1 (fr) * 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
FR2930890B1 (fr) * 2008-05-06 2010-12-10 Univ Claude Bernard Lyon Nouveaux agents de radiotherapie ciblee ou de curietherapie a base d'oxydes ou d'oxo-hydroxydes de terre rare
WO2009142754A1 (en) * 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
FR2959502B1 (fr) 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
EP3634497A2 (en) 2017-06-09 2020-04-15 Nh Theraguix Method for synthesizing silica nanoparticles
EP3424533A1 (en) 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
FR3072281B1 (fr) 2017-10-13 2020-12-04 Nh Theraguix Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs
JP7431940B2 (ja) 2019-07-29 2024-02-15 エヌアッシュ テラギ 腫瘍を治療するための方法
FR3099883A1 (fr) 2019-08-14 2021-02-19 Nh Theraguix Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence
EP3795178A1 (en) 2019-09-19 2021-03-24 Nh Theraguix Methods for triggering m1 macrophage polarization

Also Published As

Publication number Publication date
US20180264145A1 (en) 2018-09-20
DK2563408T3 (da) 2019-07-15
US10987435B2 (en) 2021-04-27
US20230109283A1 (en) 2023-04-06
PT2563408T (pt) 2019-07-15
US20180008729A1 (en) 2018-01-11
US20130195766A1 (en) 2013-08-01
TR201909432T4 (tr) 2019-07-22
SI2563408T1 (sl) 2019-08-30
ES2731649T3 (es) 2019-11-18
EP2563408A2 (fr) 2013-03-06
FR2959502B1 (fr) 2012-09-07
FR2959502A1 (fr) 2011-11-04
WO2011135101A2 (fr) 2011-11-03
EP2563408B1 (fr) 2019-04-10
HUE044384T4 (hu) 2020-10-28
US11497818B2 (en) 2022-11-15
US12533426B2 (en) 2026-01-27
HUE044384T2 (hu) 2019-10-28
EP3517136A1 (fr) 2019-07-31
WO2011135101A3 (fr) 2012-05-31

Similar Documents

Publication Publication Date Title
PL2563408T3 (pl) Ultradrobne nanocząstki z funkcjonalizowaną matrycą poliorganosiloksanową i zawierające kompleksy metali; sposoby ich wytwarzania i ich zastosowania w obrazowaniu medycznym
ZA201206810B (en) Method and device for producing microparticles or nanoparticles
GB0913442D0 (en) Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
GB201009455D0 (en) Nanoparticles and their uses in molecular imaging
ZA201200902B (en) Metallic nanoparticles, preparation and uses thereof
IL236424A0 (en) A system and method for imaging or tomography in scattering mediums
PL2468319T3 (pl) Nowy nanoprodukt przydatny w zabiegach profilaktycznych, diagnostycznych oraz leczniczych w medycynie ludzkiej i w weterynarii
IL221035A0 (en) Cancer diagnosis and imaging
PL2161075T3 (pl) Sposób i urządzenie do wytwarzania związków metaloorganicznych w proszku
PL2713340T3 (pl) Sposoby i urządzenia do lokalizowania obiektu w obrazowaniu tomografii komputerowej TK
IL226250A0 (en) Specially designed magnesium–aluminum alloys and their medical uses in a hemodynamic environment
EP2586815A4 (en) WATER-SOLUBLE POLYMER AND WATER SOLUBLE NANOPARTICLE COMPOSITE
IL217748A0 (en) Methods and compositions for diagnostics use in cancer patients
IL236062A0 (en) In vitro diagnostic device and its uses
GB201016411D0 (en) In vivo imaging method for cancer
ZA201408389B (en) Co-current and counter current resin-in-leach in gold leaching processes
IL210408A0 (en) Incorporation of mathematical constraints in methods for dose reduction and image enhancement in tomography
GB201016038D0 (en) In vivo imaging method
EP2905356A4 (en) METALLIC MATERIAL FOR ELECTRONIC COMPONENTS AND METHOD FOR PRODUCING THE SAME
EP2632505A4 (en) MATERIAL FOR MEDICAL USE COMPRISING NANOPARTICLES HAVING SUPERPARAMAGNETIC PROPERTIES AND USE THEREOF IN SURGERY
GB0914446D0 (en) Bioconjugates and their uses in imaging
PL2565184T3 (pl) Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera
GB201012209D0 (en) In vivo imaging agent
GB201012098D0 (en) Method and apparatus for forming nanoparticles
GB0909128D0 (en) Imaging method and use thereof